Pieris Pharmaceuticals Inc (PIRS)

[Seel]

Great info in this q1 earnings call. http://seekingalpha.com/article/3974584-pieris-pharmaceuticals-pirs-ceo-stephen-yoder-q1-2016-results-earnings-call-transcript
$ thru 2016. Platform development optimal.
"Our key objectives for 2016 are several and include the completion of our first-in-patient trial for PRS-080 in anemia, which is a prerequisite for establishing proof of concept in our targeted anemia patient population. It also includes continued progress for both PRS-060 in asthma and PRS-343 in HER2 solid tumors, with an anticipated initiation of first-in-man trials for each program in the first half of 2017; continued progress with our immuno-oncology multi-specifics franchise in general, including PRS-342 , working towards developing yet novel therapies with meaningful differentiation over conventional antibody approaches; also includes leveraging our licensing agreement with Enumeral to develop novel PD1-based multi-specific checkpoint blockade offering differentiation over current PD1 antibody approaches, and finally, potentially securing additional partnerships as further validation of our Anticalin drug platform."
I continue to be a buyer of PIRS and look forward to 2017/18, when its pipeline will be a little more grown up.